Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker
Authors' conclusion
Normalizing data relative to creatinine excretion will facilitate including data from males and females in a single analysis.
Study context
- Population
- Healthy volunteers without diabetes, eGFR >60 mL/min/1.73m2
- Participants
- 30 healthy volunteers
- Outcome
- Acute changes in mean biomarker levels after canagliflozin 300 mg
Methodological detailssingle-group
- Single-group
Main finding
As reported in the abstract
FPG change, mg/dL (P = 6 × 10-5)
−4.1
Serum creatinine change, mg/dL (P = 8 × 10-4)
+0.05
Serum uric acid change, mg/dL (P = 5 × 10-10)
−0.90
Further findings
Sex effect on glucosuria
- Males' responses greater when normalized to body surface area
- ≈60%
- Males and females similar when expressed as g urinary glucose per g creatinine
Correlates of glucosuria magnitude
- Glucosuria not significantly correlated with FPG, eGFR or age
Original publication
Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker. Diabetes Obes Metab. Published 22 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →